Nanobiotix Stock Soars to €41.62, Marking a 1,238% Increase Over the Year

An Upward Trend That Extends Yesterday's Record

Today's session extends the momentum started earlier in the week. Yesterday, the stock reached a new all-time high of €44.44 intraday, before settling back to €40.26 at close. It has rebounded today to €41.62. The stock has gained 43% over the week and more than 102% over three months. This dynamic originates from the FDA's recent approval of an amendment to the Phase 3 NANORAY-312 trial protocol, announced a few days ago. The amendment, submitted by Johnson & Johnson as the global sponsor, modifies the analysis framework of the study on head and neck cancer and could accelerate the development timeline of the candidate JNJ-1900 (NBTXR3). Despite this, the broader index context remains unsteady. The CAC 40 is down 0.32% at 7,954 points, and the SBF 120 has fallen by 0.23%. Nanobiotix is among the top performers in the SBF 120, behind Vallourec (+8.96%) and Soitec (+8.47%).

Technical Setup Tense After the Surge

The movement has left indicators in a tension zone. The price has moved above the upper Bollinger band (€39.95), at 109% of the band. This setup signals a potential overbought state. The RSI at 73 confirms this reading, just above the traditionally associated overbought threshold of 70. The gap with moving averages has widened: the price is 36.5% above the MM20 (€30.49) and more than double the MM200 (€18.88). The stock is approaching its technical resistance at €42.24, which is a key marker to watch if the rise continues. There are no immediate financial calendar events scheduled for the Parisian biotech. Therefore, the session is largely driven by the continuation of the buying flow observed since the FDA's green light and the upcoming developments around the NANORAY-312 trial led by Johnson & Johnson.